French AFU Cancer Committee Guidelines – Update 2024–2026: Non-muscle invasive bladder cancer (NMIBC) - 22/11/24

Doi : 10.1016/j.fjurol.2024.102742

Mathieu Roumiguié ^a,^⁎ , Priscilla Leon ^b, Evanguelos Xylinas ^c, Yves Allory ^d, François Audenet ^e, Anne Sophie Bajeot ^a, Gautier Marcq ^f, Doriane Prost ^g, Constance Thibault ^h, Alexandra Masson-Lecomte ⁱ, Thomas Seisen ^j, Benjamin Pradère ^k, Morgan Rouprêt ^j, Yann Neuzillet ^l
^a Urology Department, Toulouse University Hospital, University of Toulouse UT3, Toulouse, France
^b Urology Department, Clinique Pasteur, Royan, France
^c Urology Department, Hôpital Bichat–Claude-Bernard, AP–HP, Université Paris Cité, Paris, France
^d Department of Pathology, Institut Curie, Université Paris Saclay, Saint-Cloud, France
^e Department of Urology, Hôpital européen Georges-Pompidou, AP–HP Centre, Université Paris Cité, Paris, France
^f Urology Department, Claude Huriez Hospital, CHU de Lille, Université de Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020-U1277, Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER), 59000 Lille, France
^g Urology Department, Paris Saint-Joseph Hospital, Sorbonne University, Paris, France
^h Medical Oncology Department, Hôpital européen Georges-Pompidou, AP–HP Centre, Université Paris Cité, Paris, France
ⁱ Department of Urology, Hôpital Saint-Louis, AP–HP, Université Paris Cité, Paris, France
^j Sorbonne University, GRC 5 Predictive Onco-Uro, AP–HP, Urology, Hôpital Pitié-Salpetrière, 75013 Paris, France
^k UROSUD Urology Department, Clinique Croix Du Sud, 31130 Quint-Fonsegrives, France
^l Urology Department, Hôpital Foch, Université Paris Saclay, Suresnes, France

^⁎Corresponding author. Urology Department, Toulouse University Hospital, 1, avenue Pr.-Jean-Poulhès, 31059 Toulouse, France.Urology Department, Toulouse University Hospital1, avenue Pr.-Jean-PoulhèsToulouse31059France

Abstract

Objective

To update the CCAFU recommendations for the management of non-muscle invasive bladder cancer (NMIBC).

Methods

A systematic review (Medline) of the literature from 20222024 was performed, taking into account the elements of diagnosis, treatment options and monitoring of NMIBC and evaluating references with their level of evidence.

Results

The diagnosis of NMIBC (Ta, T1, or CIS) is made after complete and deep tumour resection. The use of bladder photodynamic diagnosis and the indication for a second TURBT (4 to 6weeks later) help to improve the initial diagnosis. The risk of recurrence and/or tumour progression is assessed via the EORTC score. By stratifying patients into low-, intermediate- and high-risk groups, adjuvant treatment can be proposed, including endovesical instillations of chemotherapy (immediate postoperative regimen), BCG (induction and maintenance regimen), or even the indication of cystectomy for unresponsive patients.

Conclusion

Updating the CCAFU's recommendations should help improve patient management, as well as the diagnosis and treatment of NMIBC.

Le texte complet de cet article est disponible en PDF.

Keywords : Urinary cytology, Bladder tumours, Cancer, Cystectomy, Survival

Plan

Export

Vol 34 - N° 12

Article 102742- novembre 2024 Retour au numéro

Article précédent

French AFU Cancer Committee Guidelines – Update 2024–2026: Testicular germ cell cancer
Thibaut Murez, Aude Fléchon, Nicolas Branger, Pierre-Henri Savoie, Laurence Rocher, Philippe Camparo, Paul Neuville, Agathe Escoffier, Morgan Rouprêt

| Article suivant

French AFU Cancer Committee Guidelines – Update 2024–2026: Muscle-invasive bladder cancer (MIBC)
Mathieu Roumiguié, Gautier Marcq, Yann Neuzillet, Anne Sophie Bajeot, Yves Allory, Paul Sargos, Priscilla Leon, François Audenet, Evanguelos Xylinas, Benjamin Pradère, Doriane Prost, Thomas Seisen, Constance Thibault, Alexandra Masson-Lecomte, Morgan Rouprêt

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

French AFU Cancer Committee Guidelines – Update 2024–2026: Non-muscle invasive bladder cancer (NMIBC) - 22/11/24

Abstract

Objective

Methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL